News

The Cystic Fibrosis Foundation is investing up to $2 million in Nanite to develop new non-viral methods of delivering gene therapies into the lungs of people with cystic fibrosis (CF). “We’re thrilled to announce this investment from the Cystic Fibrosis Foundation, which we will use to explore…

A better growth trajectory over the first years of life was associated with more favorable lung function at age 6 for children with cystic fibrosis (CF) in the U.S., a study reported. Children who were consistently above the 50th percentile in size through age 5 — as recommended by…

AR-501, an experimental, nonantibiotic inhaled treatment for chronic lung infections in cystic fibrosis (CF), was well tolerated among adults patients in a Phase 2a clinical trial. Top-line data, announced by the therapy’s developer Aridis Pharmaceuticals, suggest that the medication was present in lung fluid samples at concentrations…

Use of Kaftrio (elexacaftor/tezacaftor/ivacaftor) may help people with cystic fibrosis (CF) and the F508del mutation in both CFTR gene copies live to a median age of 71.6 and possibly longer if treatment is started in adolescence, a U.K.-based study reported. In a scenario where treatment with Kaftrio — sold…

The first two patients have been dosed in the SPAN clinical trial testing a new formulation of adrulipase, a yeast-derived enzyme, to treat exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis (CF). The open-label Phase 2 study (NCT05719311) is enrolling adult patients at three sites, one each in Florida, Illinois,…

Neither exercise nor nutritional interventions were found to affect the microbial population — typically an underlying cause of lung function decline and disease progression in cystic fibrosis (CF) — in the lung and gut of people with CF, a study in Germany shows. That microbial population remained stable despite…

Applications are being accepted for the Cystic Fibrosis Foundation‘s 2023 CFF Impact Grant program, which funds projects or programs to improve the lives of those with cystic fibrosis (CF) or their families. “The best ideas come from personal experience, and no one knows the ins and outs…

AP-PA02, an experimental phage therapy for people with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa respiratory infections, was well tolerated and reduced the bacterial load in the lungs, according to top-line results from a Phase 1b/2a trial. High doses of AP-PA02 were associated with durable reductions in bacterial load in the SWARM-Pa study. Pharmacokinetics data,…

An antibiotic susceptibility kit, called AtbFinder, helped doctors choose effective antibiotics against lung infection caused by hard-to-treat Pseudomonas aeruginosa in four hours, and this led to fewer hospital stays, less use of systemic antibiotics, and better outcomes for people with cystic fibrosis (CF), according to a small…

The IRT test, commonly used for screening newborn for cystic fibrosis (CF), is most accurate when performed between three to six days after at-term babies have been born, a study shows. A repeat IRT test may be diagnostically useful in certain cases, such as for very pre-term babies,…